Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company with multiple product candidates in development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. The Company develops immunotherapies based on cutting-edge Toll-Like Receptor biology and its ability to modulate the immune system.

Dynavax Technologies Corporation's clinical-stage product candidates include HBsAg-1018 is an adult hepatitis B vaccine in Phase 3 development that utilizes a proprietary TLR9 agonist to elicit a focused immune response designed to provide protection against hepatitis B; and the Company's lead cancer immunotherapy compound, SD-101, is a TLR9 agonist designed specifically for cancer and capable of maximal type 1 IFN induction and efficient maturation of plasmacytoid dendritic cells to antigen-presenting cells. 

Employee Rating

3.3More
TypePublic
HQBerkeley, US
Founded1996
Size (employees)251 (est)
Websitedynavax.com
Dynavax Technologies was founded in 1996 and is headquartered in Berkeley, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Dynavax Technologies

Steven N. Gersten

Steven N. Gersten

Vice President and General Counsel
Robert Janssen

Robert Janssen

Chief Medical Officer and Senior Vice President, Clinical Development
Michael S. Ostrach

Michael S. Ostrach

Senior Vice President, Chief Financial Officer and Chief Business Officer
Show more

Dynavax Technologies Office Locations

Dynavax Technologies has an office in Berkeley
Berkeley, (HQ)
100 2929 Seventh Street
Show all (1)
Report incorrect company information

Dynavax Technologies Financials and Metrics

Dynavax Technologies Revenue

Dynavax Technologies's revenue was reported to be $327 k in FY, 2017
USD

Revenue (Q3, 2018)

1.5m

Net income (Q3, 2018)

(40.5m)

EBIT (Q3, 2018)

(38.9m)

Market capitalization (4-Dec-2018)

664.5m

Closing stock price (4-Dec-2018)

10.6

Cash (30-Sep-2018)

38.7m

EV

726.1m
Dynavax Technologies's current market capitalization is $664.5 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

11.3m11.0m4.1m11.0m327.0k

Revenue growth, %

(2%)(63%)173%

General and administrative expense

25.9m17.4m22.2m37.3m27.4m

R&D expense

50.9m84.6m86.9m84.5m65.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

3.5m3.0m2.2m627.0k1.6m1.2m942.0k2.6m162.0k148.0k105.0k53.0k165.0k1.3m1.5m

General and administrative expense

5.8m4.2m4.1m4.1m4.9m5.1m5.5m8.2m9.2m11.8m6.5m5.6m6.0m16.9m15.7m15.8m

R&D expense

11.8m13.2m23.6m28.1m22.2m19.7m24.1m20.1m22.8m23.2m16.3m14.8m16.4m19.0m16.3m16.8m

Operating expense total

18.5m17.5m27.9m32.3m27.1m24.8m29.6m28.2m31.9m35.0m25.6m20.4m22.4m38.5m39.4m40.4m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

23.1m49.5m44.8m24.3m26.6m

Accounts Receivable

1.6m727.0k1.4m

Inventories

1.4m4.1m2.4m6.8m312.0k

Current Assets

192.4m127.4m199.9m89.6m198.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

12.2m26.8m17.0m19.7m14.7m36.5m103.0m38.9m24.8m23.0m21.5m37.7m20.1m36.1m28.7m38.7m

Accounts Receivable

2.2m1.7m1.3m727.0k909.0k657.0k1.2m1.2m

Inventories

550.0k5.1m12.5m

Current Assets

79.8m181.7m160.6m134.9m102.0m97.9m224.3m170.7m147.1m117.5m89.7m132.2m197.1m255.4m226.3m198.8m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(66.7m)(90.7m)(106.8m)(112.4m)(95.2m)

Depreciation and Amortization

1.3m1.4m1.4m2.3m3.2m

Inventories

677.0k(2.7m)1.6m560.0k(312.0k)

Accounts Payable

(657.0k)(523.0k)1.2m1.2m(1.9m)
Quarterly
USDY, 2018

EV/EBIT

-18.7 x

EV/CFO

-7.4 x

Debt/Equity

1 x

Debt/Assets

0.4 x

Financial Leverage

2.4 x
Show all financial metrics

Dynavax Technologies Operating Metrics

FY, 2016

Patents (Foreign)

260

Patents Pending

40

Phase III Trials Products

1

Preclinical Phase Products

2
Show all operating metrics

Dynavax Technologies Revenue Breakdown

Embed Graph

Dynavax Technologies revenue breakdown by business segment: 8.0% from Service and license revenue, 88.5% from Collaboration revenue and 3.5% from Other

Report incorrect company information

Dynavax Technologies Company Life and Culture

Report incorrect company information

Dynavax Technologies Frequently Asked Questions

  • When was Dynavax Technologies founded?

    Dynavax Technologies was founded in 1996.

  • Who are Dynavax Technologies key executives?

    Dynavax Technologies's key executives are Steven N. Gersten, Robert Janssen and Michael S. Ostrach.

  • How many employees does Dynavax Technologies have?

    Dynavax Technologies has 251 employees.

  • What is Dynavax Technologies revenue?

    Latest Dynavax Technologies annual revenue is $327 k.

  • What is Dynavax Technologies revenue per employee?

    Latest Dynavax Technologies revenue per employee is $1.3 k.

  • Who are Dynavax Technologies competitors?

    Competitors of Dynavax Technologies include Kiniksa Pharmaceuticals, Sartorius Stedim BioOutsource and Neurosearch.

  • Where is Dynavax Technologies headquarters?

    Dynavax Technologies headquarters is located at 100 2929 Seventh Street, Berkeley.

  • Where are Dynavax Technologies offices?

    Dynavax Technologies has an office in Berkeley.

  • How many offices does Dynavax Technologies have?

    Dynavax Technologies has 1 office.